2002
2003
2004
2005
2006
2007
2008
2009
2011
2013
2015
2010
2012
2014
2016
2017
PRIMARY OUTCOME MEASURE
TRIAL SIZE
DATES:
MECHANISM:
MGLUR5 ANTAGONIST
GABA ACTIVATOR
OTHER
FRAGILE X BEHAVIORS
LANGUAGE
BRAIN ACTIVITY, CLINICAL IMPRESSION
ANXIETY, DEPRESSION
SOCIAL AVOIDANCE
IRRITABILITY
SOCIAL AVOIDANCE
CLINICAL IMPRESSION
INATTENTION
CLINICAL IMPRESSION
LETHARGY/SOCIAL WITHDRAWAL
COGNITION AND LANGUAGE
MEMORY
SAFETY
EYE CONTACT
HYPERACTIVITY
EXECUTIVE FUNCTION
LANGUAGE
FRAGILE X BEHAVIORS
FRAGILE X BEHAVIORS
F
R
A
GILE X
DRUG TRIALS
HOVER OVER PARTS OF THE GRAPHIC FOR MORE INFORMATION
hover graphic:
DATE+REF
button:
BDATE+REF
BSIZE+REF
BOUTCOME+REF
BNOTE+REF
1
REFERENCE
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
2003
2005
2007
2009
2011
2013
2015
2017
2018
MINOCYCLINE AND LOVASTATIN
ACAMPROSATE, LOVASTATIN AND MINOCYCLINE
MAVOGLURANT AND BEHAVIORAL INTERVENTION
METADOXINE
TROFINETIDE
ACAMPROSATE
BASIMGLURANT
GANAXOLONE
SERTRALINE
MAVOGLURANT (ADOLESCENTS)
MAVOGLURANT (ADULTS)
MAVOGLURANT (ADULTS)
ARBACLOFEN (ADULTS AND ADOLESCENTS)
MINOCYCLINE
ASCORBIC ACID / ALPHA-TOCOPHEROL
DONEPEZIL
ARBACLOFEN
OXYTOCIN
AMPAKINE
ARBACLOFEN (CHILDREN)
LOVASTATIN AND BEHAVIORAL INTERVENTION
(
NOTE
)
(NOTE)
(
NOTE
)